The global cystic fibrosis therapeutics market accounted for USD 12.53 billion in 2023 and is expected to reach USD 146.13 billion by 2034 with a CAGR of 25.02% during the forecast period 2024-2034. The market will grow as a result of the rising incidence of cystic fibrosis, improvements in treatment options, government support and initiatives, a growing pipeline of therapeutic candidates, and strategic alliances and collaborations.
A key factor propelling the market is the increased incidence of cystic fibrosis in the globe. The need for therapeutic interventions has been driven by the discovery of more instances as a result of improved diagnostic methods and raised awareness. Research and development in the field of cystic fibrosis have been actively promoted by numerous governments and healthcare organizations worldwide. This involves providing financial support for patient assistance programs, regulatory clearances, and clinical trials, all of which promote market expansion. For instance, in October 2023, the US FDA expanded Trikafta's license to include youngsters as young as 2 years old who have at least one copy of the F508del mutation in their treatment of cystic fibrosis.
By drug class, the cystic fibrosis transmembrane conductance regulator (CFTR) modulators segment accounted for the highest revenue-grossing segment in the global cystic fibrosis therapeutics market in 2023 and is estimated to grow at the fastest CAGR during the forecast period owing to the rapid pace of research and development, continuous improvements in drug formulations, and increasing adoption of precision medicine approaches tailored to individual patients' genetic profiles. For instance, AbbVie and The Bill & Melinda Gates Foundation announced in February 2024 that they would be working together to develop and market novel therapies for genetic disorders, such as cystic fibrosis, in low- and middle-income nations.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global cystic fibrosis therapeutics market in 2023 and is estimated to grow at the fastest CAGR during the forecast period owing to the convenience and ease of administration, improved patient compliance, advancements in drug delivery technologies facilitating better bioavailability, and a shift towards oral formulations as preferred treatment options. For instance, Vertex announced encouraging outcomes in April 2024 from a Phase 2 proof-of-concept clinical trial assessing VX-561, a potential next-generation corrector, in individuals with cystic fibrosis.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global cystic fibrosis therapeutics market in 2023 owing to the increased prevalence of cystic fibrosis-related complications requiring specialized care and treatment within hospital settings, alongside the availability of a wide range of therapeutic options and comprehensive medical support services. For instance, Genentech said in October 2023 that the FDA had approved a new indication for their cystic fibrosis medication, allowing young patients ages 6 to 11 to use it. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital health solutions, rising preference for convenient and discreet medication procurement, expanding internet penetration, and the growing trend towards telemedicine and remote healthcare services.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of cystic fibrosis cases, early adoption of advanced therapeutic options, and strong presence of key market players and research institutions specializing in cystic fibrosis treatment. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, rising awareness about cystic fibrosis, increasing healthcare expenditure, and growing initiatives by governments and healthcare organizations to improve access to advanced therapeutics. For instance, Novartis published encouraging initial results in February 2024 from a Phase 3 clinical trial assessing its CFTR modulator treatment in patients with cystic fibrosis.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
A key factor propelling the market is the increased incidence of cystic fibrosis in the globe. The need for therapeutic interventions has been driven by the discovery of more instances as a result of improved diagnostic methods and raised awareness. Research and development in the field of cystic fibrosis have been actively promoted by numerous governments and healthcare organizations worldwide. This involves providing financial support for patient assistance programs, regulatory clearances, and clinical trials, all of which promote market expansion. For instance, in October 2023, the US FDA expanded Trikafta's license to include youngsters as young as 2 years old who have at least one copy of the F508del mutation in their treatment of cystic fibrosis.
By drug class, the cystic fibrosis transmembrane conductance regulator (CFTR) modulators segment accounted for the highest revenue-grossing segment in the global cystic fibrosis therapeutics market in 2023 and is estimated to grow at the fastest CAGR during the forecast period owing to the rapid pace of research and development, continuous improvements in drug formulations, and increasing adoption of precision medicine approaches tailored to individual patients' genetic profiles. For instance, AbbVie and The Bill & Melinda Gates Foundation announced in February 2024 that they would be working together to develop and market novel therapies for genetic disorders, such as cystic fibrosis, in low- and middle-income nations.
By route of administration, the oral segment accounted for the highest revenue-grossing segment in the global cystic fibrosis therapeutics market in 2023 and is estimated to grow at the fastest CAGR during the forecast period owing to the convenience and ease of administration, improved patient compliance, advancements in drug delivery technologies facilitating better bioavailability, and a shift towards oral formulations as preferred treatment options. For instance, Vertex announced encouraging outcomes in April 2024 from a Phase 2 proof-of-concept clinical trial assessing VX-561, a potential next-generation corrector, in individuals with cystic fibrosis.
By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global cystic fibrosis therapeutics market in 2023 owing to the increased prevalence of cystic fibrosis-related complications requiring specialized care and treatment within hospital settings, alongside the availability of a wide range of therapeutic options and comprehensive medical support services. For instance, Genentech said in October 2023 that the FDA had approved a new indication for their cystic fibrosis medication, allowing young patients ages 6 to 11 to use it. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing adoption of digital health solutions, rising preference for convenient and discreet medication procurement, expanding internet penetration, and the growing trend towards telemedicine and remote healthcare services.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, high prevalence of cystic fibrosis cases, early adoption of advanced therapeutic options, and strong presence of key market players and research institutions specializing in cystic fibrosis treatment. Additionally, the Asia Pacific region is estimated to grow at the fastest CAGR during the forecast period owing to the rapidly expanding healthcare infrastructure, rising awareness about cystic fibrosis, increasing healthcare expenditure, and growing initiatives by governments and healthcare organizations to improve access to advanced therapeutics. For instance, Novartis published encouraging initial results in February 2024 from a Phase 3 clinical trial assessing its CFTR modulator treatment in patients with cystic fibrosis.
This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Drug Class, Route of Administration, and Distribution Channel
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
Segmentation: Cystic Fibrosis Therapeutics Market Report 2023 - 2034
Cystic Fibrosis Therapeutics Market Analysis & Forecast by Drug Class 2023 - 2034 (Revenue USD Bn)
- Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
- Bronchodilators
- Mucolytic
- Pancreatic Enzyme Supplement
- Others
Cystic Fibrosis Therapeutics Market Analysis & Forecast by Route of Administration 2023 - 2034 (Revenue USD Bn)
- Oral
- Parenteral
- Others
Cystic Fibrosis Therapeutics Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Retail Pharmacies and Drug Stores
- Online Pharmacies
- Hospital Pharmacies
Cystic Fibrosis Therapeutics Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Cystic Fibrosis Therapeutics Market: Drug Class Estimates & Trend Analysis
8. Cystic Fibrosis Therapeutics Market: Route of Administration Estimates & Trend Analysis
9. Cystic Fibrosis Therapeutics Market: Distribution Channel Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Cystic Fibrosis Therapeutics Market
12. Europe Global Cystic Fibrosis Therapeutics Market
13. Asia Pacific Global Cystic Fibrosis Therapeutics Market
14. Latin America Global Cystic Fibrosis Therapeutics Market
15. MEA Global Cystic Fibrosis Therapeutics Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Vertex Pharmaceuticals Incorporated
- AbbVie Inc.
- Genentech (Roche)
- Gilead Sciences Inc.
- Novartis AG
- Chiesi Farmaceutici S.p.A.
- Merck & Co. Inc.
- Boehringer Ingelheim International GmbH
- Mylan N.V.
- Proteostasis Therapeutics Inc.
- Galapagos NV
- Celtaxsys Inc.
- Translate Bio Inc.
- Zambon S.p.A.
- PTC Therapeutics Inc.
